The peptide landscape for weight management has shifted dramatically since 2023, driven primarily by GLP-1 receptor agonists and newer multi-receptor compounds entering clinical trials. Several peptides now have robust Phase 3 data demonstrating significant body weight reduction, while others remain in earlier research stages with promising but less definitive evidence.
This guide ranks eight peptides by the strength of their clinical evidence for weight loss, the magnitude of documented weight reduction, and their current or anticipated regulatory status. We prioritize compounds with published human trial data over those with only preclinical evidence, and FDA-approved compounds over investigational ones.
Important: All peptides discussed here are prescription medications or investigational compounds. This guide is for educational purposes only and does not constitute medical advice. Weight management decisions should be made with a qualified healthcare provider who can assess individual risk factors, contraindications, and treatment goals.
Semaglutide
Best for: Overall evidence-backed weight loss with established long-term safety data
Semaglutide (Wegovy/Ozempic) is the most extensively studied peptide for weight loss, with Phase 3 STEP trial data demonstrating approximately 15-17% body weight reduction over 68 weeks. It is FDA-approved for chronic weight management and has the largest real-world evidence base of any weight-loss peptide.
Tirzepatide
Best for: Maximum weight loss magnitude from a single FDA-approved agent
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP receptor agonist that demonstrated up to 22.5% body weight reduction in the SURMOUNT-1 trial — the highest weight loss recorded for any single-agent peptide in Phase 3 trials. Its dual-receptor mechanism may offer advantages over GLP-1-only agents for some individuals.
Liraglutide
Best for: Established first-generation GLP-1 option with the longest safety track record
Liraglutide (Saxenda) was the first GLP-1 receptor agonist approved for weight management, demonstrating approximately 8% body weight reduction in the SCALE trials. While outperformed by semaglutide and tirzepatide on efficacy, it has the longest post-marketing safety record and remains a well-established option.
Retatrutide
Best for: Emerging triple-agonist with the highest weight loss seen in Phase 2 data
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that showed up to 24% body weight reduction in a Phase 2 trial — potentially exceeding tirzepatide. Phase 3 trials are underway. It is not yet approved and carries the inherent uncertainty of an investigational compound, but its triple-receptor mechanism represents the next frontier in incretin-based therapy.
Survodutide
Best for: Investigational dual-agonist with potential liver fat benefits
Survodutide is a dual GLP-1/glucagon receptor agonist being developed by Boehringer Ingelheim. Phase 2 data showed approximately 18-19% weight loss, and its glucagon component may offer additional benefits for liver fat reduction. It remains in clinical development without FDA approval.
AOD-9604
Best for: GH-fragment approach to fat metabolism without full-length GH side effects
AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that has been studied for its lipolytic properties. It showed modest fat loss in early clinical trials without the diabetogenic effects of full-length GH. Evidence is limited compared to GLP-1 agents, and it is not FDA-approved for weight loss. It remains popular in the research and compounding community.
Tesamorelin
Best for: FDA-approved visceral fat reduction via the GH-release pathway
Tesamorelin (Egrifta) is a GHRH analog FDA-approved specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy. It stimulates endogenous GH release, which promotes lipolysis. Its weight loss effect is modest compared to GLP-1 agents, but it targets visceral fat specifically and has FDA-approved status for its indication.
CagriSema
Best for: Dual amylin/GLP-1 combination for enhanced satiety signaling
CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide in a single injection. Phase 3 data from the REDEFINE program showed approximately 22-24% body weight reduction, rivaling or exceeding tirzepatide. It targets two distinct satiety pathways — GLP-1 and amylin — and is anticipated for regulatory submission.
Frequently asked questions
Based on clinical trial data, tirzepatide has demonstrated the highest single-agent weight loss in Phase 3 trials (up to 22.5% body weight reduction), while retatrutide showed up to 24% in Phase 2 data. Semaglutide remains the most extensively studied with the broadest evidence base. The best choice depends on individual factors, regulatory approval status, and prescriber assessment.
FDA-approved GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) have undergone rigorous clinical trials and post-marketing surveillance. Common side effects include nausea, vomiting, and diarrhea, particularly during dose titration. Serious but rare risks include pancreatitis and potential thyroid concerns (boxed warning for medullary thyroid carcinoma based on rodent studies). Non-approved peptides have less safety data. All weight loss peptides should be used under medical supervision.
FDA-approved weight loss peptides — semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) — require a prescription. They are typically prescribed after evaluation of BMI, comorbidities, and prior weight loss attempts. Research peptides like AOD-9604 are not FDA-approved and their legal availability varies by jurisdiction.
GLP-1 receptor agonists typically produce noticeable appetite suppression within the first 1-2 weeks, with measurable weight loss beginning in the first month. Clinical trials measure primary endpoints at 52-72 weeks. Most protocols involve gradual dose titration over 4-8 weeks to minimize gastrointestinal side effects.
Clinical data from the STEP 1 trial extension showed that participants regained approximately two-thirds of lost weight within one year of discontinuing semaglutide. This suggests that GLP-1-based weight loss peptides require ongoing use to maintain results, similar to other chronic disease medications. Lifestyle modifications during treatment may help attenuate regain.
CagriSema (cagrilintide + semaglutide) is a clinically studied combination targeting two different satiety pathways. Combining FDA-approved weight loss peptides outside of studied protocols is not recommended without medical guidance, as additive GI side effects and other risks may occur. Never combine peptides without prescriber oversight.